$BNTX · BioNTech SE
BioNTech reported Q3 2026 revenues of €1,289.2 million, down from €1,518.9 million YoY, while swinging to an IFRS net profit of €184.5 million (€0.73 diluted EPS) from a €28.7 million loss. The company raised its full-year 2026 revenue guidance midpoint, narrowing the range to €1.7–€1.9 billion. Adjusted R&D and SG&A expense guidance was maintained at €2.0–€2.3 billion and €700–€800 million respectively.
- Q3 2026 revenues of €1,289.2M vs €1,518.9M YoY, driven by lower COVID-19 vaccine demand
- IFRS net profit swung to €184.5M (€0.73 diluted EPS) from a €28.7M loss in Q3 2025
- Adjusted net profit was €440.9M (€1.76 diluted EPS) vs €752.5M (€3.11) in Q3 2025
- Full-year 2026 revenue guidance raised to €1.7–€1.9B from prior €1.6–€1.9B range
- Cash, cash equivalents and security investments stood at €16.2B as of September 30, 2026
Extended-hours trading shows BNTX at $90.07, up +2.90% vs the regular close of $87.53, indicating a positive initial reaction to the guidance raise and return to quarterly profitability.
BioNTech delivered a return to quarterly profitability alongside a guidance raise, signaling that its oncology pipeline momentum and cost discipline are beginning to offset declining COVID-19 vaccine revenues.
BioNTech's pivot from COVID-19 vaccine revenue toward oncology is accelerating with seven pivotal pumitamig trials and the first global Phase 3 combining a bispecific with an ADC. The €16.2B cash position provides a multi-year runway that few biotech peers can match.
Revenue continues to decline YoY (€1,289.2M vs €1,518.9M) as COVID-19 vaccine demand wanes. Year-to-date net loss remains deep at €1,168.2M. The oncology pipeline is still pre-commercial, and the Roche/Genentech option exercise shifts future R&D costs but also signals reduced mRNA investment scope.